lncRNA LIFR‑AS1 inhibits gastric carcinoma cell proliferation, migration and invasion by sponging miR‑4698

Zhao, Jiangqiao; Li, Xiaoning; Fu, Liping; Zhang, Na; Yang, Jun; Cai, Jun

doi:10.3892/mmr.2020.11792

Cited by 10 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chen et al reported that METTL3-mediated m 6 A hyper-methylation induced the upregulation of LIFR-AS1 in pancreatic cancer by enhancing METTL3 mRNA stability, resulting in increased expression of VEGFA by directly interacting with miR-150-5p [25]. LIFR-AS1 has been shown to act as a sponge for miR-942-5p in lung cancer [27], for miR-29a in CRC [24] and osteosarcoma [28], for miR-31-5p in thyroid carcinoma [29], for miR-4262 in glioma [30], for miRNA-150-5p in pancreatic cancer [25], for miR-197-3p in breast cancer [31], and for miR-29a-3p [26] and miR-4698 [32] in gastric cancer. These results prompted us to investigate the ceRNA function of LIFR-AS in CRC.…”

Section: Discussionmentioning

confidence: 99%

Genome-wide screening for differentially methylated long noncoding RNAs identifies LIFR-AS1 as an epigenetically regulated lncRNA that inhibits the progression of colorectal cancer

et al. 2022

View full text Add to dashboard Cite

Background Aberrant DNA methylation is an epigenetic marker that has been linked to the pathogenesis of colorectal cancer (CRC). Long noncoding RNAs (lncRNAs) have been increasingly identified to be associated with tumorigenic processes of CRC. Identifying epigenetically dysregulated lncRNAs and characterizing their effects during carcinogenesis are focuses of cancer research. Methods Differentially methylated loci and expressed lncRNAs were identified by integrating DNA methylome and transcriptome analyses using The Cancer Genome Atlas database. Bisulfite sequencing PCR (BSP) was performed to analyze LIFR-AS1 promoter methylation status. The functional roles of LIFR-AS1 in CRC were determined by in vitro and in vivo experiments. Results We identified a novel hypermethylated lncRNA, LIFR-AS1, that was downregulated and associated with tumorigenesis, metastasis, and poor prognosis in CRC. High methylation burden of LIFR-AS1 indicated a poor survival of CRC patients. Promoter hypermethylation of LIFR-AS1 in tumor tissues was confirmed by BSP. Functional assays revealed that LIFR-AS1 could competitively bind to hsa-miR-29b-3p, and repressed colon cancer cell proliferation, colony formation and invasion. LIFR-AS1 also inhibited tumor growth in a mouse xenograft model of CRC. Conclusions Our results showed that the identified DNA methylation-dysregulated lncRNAs may be potential biomarkers and highlighted a role for LIFR-AS1 as a tumor suppressor in CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Genome-wide screening for differentially methylated long noncoding RNAs identifies LIFR-AS1 as an epigenetically regulated lncRNA that inhibits the progression of colorectal cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In contrast to the above results, the expression of LIFR-AS1 has been reported to be reduced in both gastric tumor tissue and MKN45 and AGS cell lines [ 26 ]. Moreover, bioinformatic analysis and dual-luciferase reporter assays showed that LIFR-AS1 positively regulates the MTUS1 expression by sponging miR-4698, thereby inhibiting the MEK/ERK pathway.…”

Section: The Function Of Lifr-as1 In Cancer and The Underlying Molecular Mechanismsmentioning

confidence: 81%

Long Noncoding RNA LIFR-AS1: A New Player in Human Cancers

Bai

Wang

Zhang

2022

BioMed Research International

View full text Add to dashboard Cite

Emerging evidence has indicated that aberrantly expressed long noncoding RNAs (lncRNAs) play a vital role in various biological processes associated with tumorigenesis. Leukemia inhibitory factor receptor antisense RNA1 (LIFR-AS1) is a recently identified lncRNA transcribed in an antisense manner from the LIFR gene located on human chromosome 5p13.1. LIFR-AS1 regulates tumor proliferation, migration, invasion, apoptosis, and drug resistance through different mechanisms. Its expression level is related to the clinicopathological characteristics of tumors and plays a key role in tumor occurrence and development. In this review, we summarize the role of LIFR-AS1 in the development and progression of different cancers and highlight the potential for LIFR-AS1 to serve as a biomarker and therapeutic target for a variety of human cancers.

show abstract

“…The above findings suggested that MTUS1 can play a key role in the regulation of immune cell infiltration and is a CRC immune-modulating factor. Previous studies have reported that the interaction between the lncRNA LIFR-AS1 and MTUS1 can block the MEK/ ERK pathway, thereby inhibiting tumour cell proliferation, migration, and invasion [16,44]. Furthermore, the repression of the MEK/ERK pathway can change the immune cell composition of the tumour immune microenvironment [45].…”

Section: Discussionmentioning

confidence: 99%

MTUS1 is a promising diagnostic and prognostic biomarker for colorectal cancer

et al. 2022

View full text Add to dashboard Cite

Background The morbidity and mortality of colorectal cancer (CRC) remain high, posing a serious threat to human life and health. The early diagnosis and prognostic evaluation of CRC are two major challenges in clinical practice. MTUS1 is considered a tumour suppressor and can play an important role in inhibiting cell proliferation, migration, and tumour growth. Moreover, the expression of MTUS1 is decreased in different human cancers, including CRC. However, the biological functions and molecular mechanisms of MTUS1 in CRC remain unclear. Methods In the present study, data from The Cancer Genome Atlas (TCGA) database were analysed using R statistical software (version 3.6.3.) to evaluate the expression of MTUS1 in tumour tissues and adjacent normal tissues using public databases such as the TIMER and Oncomine databases. Then, 38 clinical samples were collected, and qPCR was performed to verify MTUS1 expression. We also investigated the relationship between MTUS1 expression and clinicopathological characteristics and elucidated the diagnostic and prognostic value of MTUS1 in CRC. In addition, the correlation between MTUS1 expression and immune infiltration levels was identified using the TIMER and GEPIA databases. Furthermore, we constructed and analysed a PPI network and coexpression modules of MTUS1 to explore its molecular functions and mechanisms. Results CRC tissues exhibited lower levels of MTUS1 than normal tissues. The logistic regression analysis indicated that the expression of MTUS1 was associated with N stage, TNM stage, and neoplasm type. Moreover, CRC patients with low MTUS1 expression had poor overall survival (OS). Multivariate analysis revealed that the downregulation of MTUS1 was an independent prognostic factor and was correlated with poor OS in CRC patients. MTUS1 expression had good diagnostic value based on ROC analysis. Furthermore, we identified a group of potential MTUS1-interacting proteins and coexpressed genes. GO and KEGG enrichment analyses showed that MTUS1 was involved in multiple cancer-related signalling pathways. Moreover, the expression of MTUS1 was significantly related to the infiltration levels of multiple cells. Finally, MTUS1 expression was strongly correlated with various immune marker sets. Conclusions Our results indicated that MTUS1 is a promising biomarker for predicting the diagnosis and prognosis of CRC patients. MTUS1 can also become a new molecular target for tumour immunotherapy.

show abstract

lncRNA LIFR‑AS1 inhibits gastric carcinoma cell proliferation, migration and invasion by sponging miR‑4698

Cited by 10 publications

References 49 publications

Genome-wide screening for differentially methylated long noncoding RNAs identifies LIFR-AS1 as an epigenetically regulated lncRNA that inhibits the progression of colorectal cancer

Genome-wide screening for differentially methylated long noncoding RNAs identifies LIFR-AS1 as an epigenetically regulated lncRNA that inhibits the progression of colorectal cancer

Long Noncoding RNA LIFR-AS1: A New Player in Human Cancers

MTUS1 is a promising diagnostic and prognostic biomarker for colorectal cancer

Contact Info

Product

Resources

About